Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

NCT07115238
completednot_applicable

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

NCT06151808
completedphase_1

A Study to Evaluate XTR006 in Chinese Volunteers

NCT06151795

Clinical Trials (3)

Showing 3 of 3 trials
NCT07115238Phase 3

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

Recruiting
NCT06151808Not Applicable

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

Completed
NCT06151795Phase 1

A Study to Evaluate XTR006 in Chinese Volunteers

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3